MyFinsight
Home
Blog
About
Proceeds from issuance of
common stock under the...
$2,487K
Proceeds from exercise of
common stock options
$1,896K
(63100.00%↑ Y/Y)
Net cash provided by
(used in) financing...
$3,687K
(446.85%↑ Y/Y)
Canceled cashflow
$696K
Net decrease in
cash, cash...
-$92,287K
(-113.72%↓ Y/Y)
Canceled cashflow
$3,687K
Stock-based compensation
$6,678K
(42.72%↑ Y/Y)
Other non-current
assets
-$1,541K
(-405.15%↓ Y/Y)
Non-cash lease expense
$963K
(-32.14%↓ Y/Y)
Depreciation and
amortization expense
$785K
(-22.74%↓ Y/Y)
Non-cash interest
expense
$231K
Proceeds from maturities
of...
$134,300K
(-36.29%↓ Y/Y)
Taxes paid related to
net share...
$377K
(639.22%↑ Y/Y)
Principal paid on finance
lease liabilities
$181K
(-69.98%↓ Y/Y)
Payments for offering
costs
$138K
(-66.50%↓ Y/Y)
Net cash used in
operating activities
-$81,903K
(-6.56%↓ Y/Y)
Net cash (used in)
provided by investing...
-$14,071K
(-140.50%↓ Y/Y)
Canceled cashflow
$10,198K
Canceled cashflow
$134,300K
Net loss
-$78,047K
(10.00%↑ Y/Y)
Accrued compensation
-$4,509K
(-5223.86%↓ Y/Y)
Purchases of
available-for-sale marketable...
$147,823K
(-15.94%↓ Y/Y)
Other accrued
expenses and current...
-$4,443K
(-537.30%↓ Y/Y)
Accounts payable
-$2,373K
(-145.70%↓ Y/Y)
Operating lease liability
-$1,236K
(28.18%↑ Y/Y)
Accretion of discounts on
available-for-sale marketable...
$920K
(-76.73%↓ Y/Y)
Prepaid expense and
other current assets
$526K
(126.67%↑ Y/Y)
Gain on sale of
property and equipment
$47K
Purchases of property and
equipment
$293K
(7225.00%↑ Y/Y)
Internal-use software
development costs
$255K
(27.50%↑ Y/Y)
Back
Back
Cash Flow
Kyverna Therapeutics, Inc. (KYTX)
Kyverna Therapeutics, Inc. (KYTX)
source: myfinsight.com